https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19261
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADGlecaprevir / Pibrentasvir may inhibit hepatic transports OATP1B1/B3, P-gp and BCRP and CYP 3A4 and increase plasma concentration of Atorvastatin.
–
–
–
Possible increased risk of HMG CoA inhibitor toxicity.
Avoid association. Choose an alternative.
–
Symptoms of toxicity associated with hypolipidemic agents : gastrointestinal effects, fatigue and muscular weaknesses, myalgias, muscular cramps, myopathies, rhabdomyolysis and myoglobinuria leading to renal insufficiency.
–
Reference number |
---|
# patients |
HCV |
Dose |
Frequency |
Cmax |
AUC |
3373 |
---|
11 |
- |
400/120 mg |
QD |
3373 |
---|
11 |
- |
10 mg |
QD |
+ 2100% (22x) |
+ 728% (8.3x) |
–